[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SEED Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100608130","phase-1-a-phase-11b-study-of-st-01156-a-small-molecule-rbm39-degrader-in-patients-with-advanced-solid-malignancies-100608130",false,"NCT07197554","A Phase 1\u002F1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","Inclusion Criteria:\n\n* Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.\n* Has a metastatic or locally advanced and unresectable solid tumor.\n* Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.\n* Has an ECOG performance status ≤ 2 at screening.\n* Has adequate organ function as defined in the protocol.\n\nExclusion Criteria:\n\n* Has received prior radiotherapy within 2 weeks of treatment.\n* Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable\n* Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter.\n* Had major surgery within 28 days before study therapy administration\n* Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy.\n* Has previously received a RBM39 inhibitor\u002Fdegrader.","ALL","16 Years",{"count":18,"type":19},171,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","A Phase 1\u002F1B Study of ST-01156 in Patients with Advanced Solid Malignancies",[25,26,27,28],"Advanced Solid Tumors","Ewing Sarcoma","Hepatocellular Carcinoma (HCC)","Biliary Tract Cancer (BTC)",[30,31,32,33,34,35,36,37,38,39,40],"cancer","solid tumors","RBM39","RBM39 degrader","metastatic solid malignancies","Ewing sarcoma","Hepatocellular carcinoma","HCC","Biliary tract carcinoma","endometrial carcinoma","Adolescents","RECRUITING","2026-05-30",{"date":44,"type":45},"2026-06-02","ACTUAL",{"date":47,"type":45},"2025-12-01",{"date":49,"type":19},"2029-12-31",{"name":51,"class":52},"SEED Therapeutics, Inc.","INDUSTRY",6,""]